Overcoming Process Bottlenecks in Antibody Discovery through End-to-end Automated Synthetic Biology Solutions

In this presentation, you will learn how:

• Construct synthesis is a bottleneck is antibody therapeutic development
• Recent advances in automation and synthetic biology are addressing this problem
• The BioXp® system is helping researchers to bridge the automation gap between high content sequencing and downstream characterization

Telesis Bio’s BioXp automation platform streamlines screening and optimization workflows of antibody candidates by enabling high-throughput, overnight fragment synthesis, cloning, as well as generation of antibody variant libraries, all at the push of a button.